ICML 2019 | MRD status after liso-cel in the TRANSCEND CLL-004 trial
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the MRD status of relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) patients after lisocabtagene maraleucel treatment in the TRANSCEND CLL-004 trial (NCT03331198). She also discusses the next stages for the trial, which will also look at combining the agent with ibrutinib. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
Get great new content delivered to your inboxSign up